Paraffin Embedding: The infiltrating of tissue specimens with paraffin, as a supporting substance, to prepare for sectioning with a microtome.DimethylformamidePatents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Waxes: A plastic substance deposited by insects or obtained from plants. Waxes are esters of various fatty acids with higher, usually monohydric alcohols. The wax of pharmacy is principally yellow wax (beeswax), the material of which honeycomb is made. It consists chiefly of cerotic acid and myricin and is used in making ointments, cerates, etc. (Dorland, 27th ed)Rhizomucor: A genus of zygomycetous fungi of the family Mucoraceae, order MUCORALES.Solvents: Liquids that dissolve other substances (solutes), generally solids, without any change in chemical composition, as, water containing sugar. (Grant & Hackh's Chemical Dictionary, 5th ed)Body Composition: The relative amounts of various components in the body, such as percentage of body fat.Surface-Active Agents: Agents that modify interfacial tension of water; usually substances that have one lipophilic and one hydrophilic group in the molecule; includes soaps, detergents, emulsifiers, dispersing and wetting agents, and several groups of antiseptics.Weight Lifting: A sport in which weights are lifted competitively or as an exercise.EthersAnabolic Agents: These compounds stimulate anabolism and inhibit catabolism. They stimulate the development of muscle mass, strength, and power.SwedenSolubility: The ability of a substance to be dissolved, i.e. to form a solution with another substance. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Polyethyleneimine: Strongly cationic polymer that binds to certain proteins; used as a marker in immunology, to precipitate and purify enzymes and lipids. Synonyms: aziridine polymer; Epamine; Epomine; ethylenimine polymer; Montrek; PEI; Polymin(e).Polymers: Compounds formed by the joining of smaller, usually repeating, units linked by covalent bonds. These compounds often form large macromolecules (e.g., BIOPOLYMERS; PLASTICS).Sodium Dodecyl Sulfate: An anionic surfactant, usually a mixture of sodium alkyl sulfates, mainly the lauryl; lowers surface tension of aqueous solutions; used as fat emulsifier, wetting agent, detergent in cosmetics, pharmaceuticals and toothpastes; also as research tool in protein biochemistry.Dental Etching: Preparation of TOOTH surfaces, and of materials bonded to teeth or DENTAL IMPLANTS, with agents and methods which roughen the surface to facilitate adhesion. Agents include phosphoric or other acids (ACID ETCHING, DENTAL) and methods include LASERS.Alkanesulfonic Acids: Sulfonic acid derivatives that are substituted with an aliphatic hydrocarbon group.Transition Temperature: The temperature at which a substance changes from one state or conformation of matter to another.Glass: Hard, amorphous, brittle, inorganic, usually transparent, polymerous silicate of basic oxides, usually potassium or sodium. It is used in the form of hard sheets, vessels, tubing, fibers, ceramics, beads, etc.Phase Transition: A change of a substance from one form or state to another.Calorimetry, Differential Scanning: Differential thermal analysis in which the sample compartment of the apparatus is a differential calorimeter, allowing an exact measure of the heat of transition independent of the specific heat, thermal conductivity, and other variables of the sample.Temperature: The property of objects that determines the direction of heat flow when they are placed in direct thermal contact. The temperature is the energy of microscopic motions (vibrational and translational) of the particles of atoms.Freeze Drying: Method of tissue preparation in which the tissue specimen is frozen and then dehydrated at low temperature in a high vacuum. This method is also used for dehydrating pharmaceutical and food products.Molecular Medicine: The field of medicine concerned with understanding the biochemical basis of health and disease and involved in developing diagnostic and therapeutic methods that utilize MOLECULAR BIOLOGY techniques.Histone-Lysine N-Methyltransferase: An enzyme that catalyzes the methylation of the epsilon-amino group of lysine residues in proteins to yield epsilon mono-, di-, and trimethyllysine. EC 2.1.1.43.Salivary Gland Neoplasms: Tumors or cancer of the SALIVARY GLANDS.Hair Follicle: A tube-like invagination of the EPIDERMIS from which the hair shaft develops and into which SEBACEOUS GLANDS open. The hair follicle is lined by a cellular inner and outer root sheath of epidermal origin and is invested with a fibrous sheath derived from the dermis. (Stedman, 26th ed) Follicles of very long hairs extend into the subcutaneous layer of tissue under the SKIN.Paneth Cells: Differentiated epithelial cells of the INTESTINAL MUCOSA, found in the basal part of the intestinal crypts of Lieberkuhn. Paneth cells secrete GROWTH FACTORS, digestive enzymes such as LYSOZYME and antimicrobial peptides such as cryptdins (ALPHA-DEFENSINS) into the crypt lumen.ParisNeoplastic Stem Cells: Highly proliferative, self-renewing, and colony-forming stem cells which give rise to NEOPLASMS.Detergents: Purifying or cleansing agents, usually salts of long-chain aliphatic bases or acids, that exert cleansing (oil-dissolving) and antimicrobial effects through a surface action that depends on possessing both hydrophilic and hydrophobic properties.LaunderingHousehold Products: Substances or materials used in the course of housekeeping or personal routine.Beverages: Liquids that are suitable for drinking. (From Merriam Webster Collegiate Dictionary, 10th ed)Poison Control Centers: Facilities which provide information concerning poisons and treatment of poisoning in emergencies.Laundry Service, Hospital: Hospital department which administers all activities pertaining to the hospital laundry service.Pulmonary Surfactants: Substances and drugs that lower the SURFACE TENSION of the mucoid layer lining the PULMONARY ALVEOLI.Gas, Natural: A combustible, gaseous mixture of low-molecular weight PARAFFIN hydrocarbons, generated below the surface of the earth. It contains mostly METHANE and ETHANE with small amounts of PROPANE; BUTANES; and higher hydrocarbons, and sometimes NITROGEN; CARBON DIOXIDE; HYDROGEN SULFIDE; and HELIUM. (from McGraw-Hill Dictionary of Scientific and Technical Terms, 6th ed)Chemical Industry: The aggregate enterprise of manufacturing and technically producing chemicals. (From Random House Unabridged Dictionary, 2d ed)EthanePropaneCatalysis: The facilitation of a chemical reaction by material (catalyst) that is not consumed by the reaction.Alkanes: The generic name for the group of aliphatic hydrocarbons Cn-H2n+2. They are denoted by the suffix -ane. (Grant & Hackh's Chemical Dictionary, 5th ed)Oxidation-Reduction: A chemical reaction in which an electron is transferred from one molecule to another. The electron-donating molecule is the reducing agent or reductant; the electron-accepting molecule is the oxidizing agent or oxidant. Reducing and oxidizing agents function as conjugate reductant-oxidant pairs or redox pairs (Lehninger, Principles of Biochemistry, 1982, p471).Copyright: It is a form of protection provided by law. In the United States this protection is granted to authors of original works of authorship, including literary, dramatic, musical, artistic, and certain other intellectual works. This protection is available to both published and unpublished works. (from Circular of the United States Copyright Office, 6/30/2008)Ligands: A molecule that binds to another molecule, used especially to refer to a small molecule that binds specifically to a larger molecule, e.g., an antigen binding to an antibody, a hormone or neurotransmitter binding to a receptor, or a substrate or allosteric effector binding to an enzyme. Ligands are also molecules that donate or accept a pair of electrons to form a coordinate covalent bond with the central metal atom of a coordination complex. (From Dorland, 27th ed)Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.Molecular Sequence Data: Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories.Amino Acid Sequence: The order of amino acids as they occur in a polypeptide chain. This is referred to as the primary structure of proteins. It is of fundamental importance in determining PROTEIN CONFORMATION.Ocotea: A plant genus in the LAURACEAE family. The common name of stinkwood is also used for Zieria (RUTACEAE).Endocytosis: Cellular uptake of extracellular materials within membrane-limited vacuoles or microvesicles. ENDOSOMES play a central role in endocytosis.

Aromatic L-amino acid decarboxylase: conformational change in the flexible region around Arg334 is required during the transaldimination process. (1/1033)

Aromatic L-amino acid decarboxylase (AADC) catalytic mechanism has been proposed to proceed through two consecutive intermediates (i.e., Michaelis complex and the external aldimine). Limited proteolysis of AADC that preferentially digested at the C-terminal side of Arg334 was slightly retarded in the presence of dihydroxyphenyl acetate that formed a stable Michaelis complex. On the contrary, AADC was scarcely digested in the presence of L-dopa methyl ester that formed a stable external aldimine. Similar protection by the substrate analogs was observed in the chemical modification experiment. From these results, we concluded that the region around Arg334 must be exposed and flexible in the unliganded state, and forming the Michaelis complex generated a subtle conformational change, then underwent marked conformational change during the subsequent transaldimination process prerequisite to forming the external aldimine. For further analyses, we constructed a mutant gene encoding in tandem the two peptides of AADC cleaved at the Asn327-Met328 bond inside the putative flexible region. The gene product, fragmentary AADC, was still active with L-dopa as substrate, but its k(cat) value was decreased 57-fold, and the Km value was increased 9-fold compared with those of the wild-type AADC. The absorption spectra of the fragmentary AADC in the presence of L-dopa methyl ester showed shift in the equilibrium of the transaldimination from the external aldimine to the Michaelis complex. Tryptic digestion of the fragmentary AADC removed seven amino acid residues, Met328-Arg334, and resulted in complete inactivation. Susceptibility of the fragmentary enzyme to trypsin was not changed by L-dopa methyl ester revealing the loss of appropriate conformational change in the flexible region induced by substrate binding. From these results we propose that the conformational change in the flexible region is required during the transaldimination process.  (+info)

Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis. (2/1033)

BACKGROUND: The trefoil peptides are major secretory products of mucus cells of the gastrointestinal tract and show increased expression after inflammatory or ulcerative damage. Recombinant human TFF2 (spasmolytic polypeptide) has been shown to be cytoprotective, and enhances repair in models of gastric injury. AIMS: To test the healing effects of recombinant human (h)TFF2 in a rat model of chronic colitis. METHODS: Colitis was induced by intracolonic administration of dinitrobenzene sulphonic acid in ethanol. Mucosal repair was quantified macroscopically, microscopically by image analysis of tissue histology, and by measuring myeloperoxidase activity. RESULTS: Initial validation studies showed that maximal injury and inflammation occurred at the end of the first week after colitis induction (active phase), and that spontaneous healing was complete by eight weeks. Once daily intrarectal application of hTFF2 (2.5 mg/kg; approximately 0.5 mg/rat) for five days after maximal damage had been sustained, reduced both microscopic and macroscopic injury by 80% and inflammatory index by 50% compared with vehicle controls. In addition, endogenous concentrations of rat TFF2 and TFF3 (intestinal trefoil factor) were increased in the active phase of colitis and were reduced to basal levels by hTFF2 treatment. CONCLUSIONS: This study has shown that hTFF2 enhances the rate of colonic epithelial repair, and reduces local inflammation in a rat model of colitis, and suggests that luminal application of trefoil peptides may have therapeutic potential in the treatment of inflammatory bowel disease.  (+info)

KNR4, a suppressor of Saccharomyces cerevisiae cwh mutants, is involved in the transcriptional control of chitin synthase genes. (3/1033)

The KNR4 gene, originally isolated by complementation of a K9 killer-toxin-resistant mutant displaying reduced levels of both 1,3-beta-glucan and 1,3-beta-glucan synthase activity, was recloned from a YCp50 genomic library as a suppressor of Saccharomyces cerevisiae calcofluor-white-hypersensitive (cwh) mutants. In these mutants, which were characterized by increased chitin levels, the suppressor effect of KNR4 resulted, for some of them, in a lowering of polymer content to close to wild-type level, with no effect on the contents of beta-glucan and mannan. In all cases, this effect was accompanied by a strong reduction in mRNA levels corresponding to CHS1, CHS2 and CHS3, encoding chitin synthases, without affecting expression of FKS1 and RHO1, two genes encoding the catalytic subunit and a regulatory component of 1,3-beta-glucan synthase, respectively. Overexpression of KNR4 also inhibited expression of CHS genes in wild-type strains and in two other cwh mutants, whose sensitivity to calcofluor white was not suppressed by this gene. The physiological relevance of the KNR4 transcriptional effect was addressed in two different ways. In a wild-type strain exposed to alpha-factor, overexpression of this gene inhibited CHS1 induction and delayed shmoo formation, two events which are triggered in response to the pheromone, whereas it did not affect bud formation and cell growth in a chs1 chs2 double mutant. A chimeric protein made by fusing green fluorescent protein to the C terminus of Knr4p which fully complemented a knr4delta mutation was found to localize in patches at presumptive bud sites in unbudded cells and at the incipient bud site during bud emergence. Taken together, these results demonstrate that KNR4 has a regulatory role in chitin deposition and in cell wall assembly. A mechanism by which this gene affects expression of CHS genes is proposed.  (+info)

Nitrite determination in human plasma and synovial fluid using reactions of nitric oxide with 3, 5-dibromo-4-nitrosobenzenesulphonate (DBNBS). (4/1033)

DBNBS (3,5-dibromo-4-nitrosobenzenesulphonate) reacts with nitric oxide (NO) produced from nitrite ions in acid solution to give a radical with a characteristic electron spin resonance spectrum, attributable to a 'DBNBS-NO' product, and comprising a triplet with alphaN=0.96 mT. This is identical with the spectrum obtained when NO, introduced from the gas phase, reacts with DBNBS. Under certain conditions, an additional signal is observed, attributable to oxidation of DBNBS to the radical cation, DBNBS*+ (a triplet with alphaN=1.32 mT). Conditions are described for the determination of nitrite, which avoid this DBNBS oxidation. The height of the low-field signal from the DBNBS-NO product is directly proportional to the nitrite concentration up to about 0.08 mM nitrite. The method has been applied to the measurement of nitrite concentrations in whole blood, plasma and synovial fluid taken from rheumatoid arthritis patients. In order to avoid the oxidation of DBNBS when analysing biological samples of this type, it is necessary to treat the specimen by ultrafiltration as soon as possible after collection and before addition of DBNBS.  (+info)

Deletion of new covalently linked cell wall glycoproteins alters the electrophoretic mobility of phosphorylated wall components of Saccharomyces cerevisiae. (5/1033)

The incorporation of radioactive orthophosphate into the cell walls of Saccharomyces cerevisiae was studied. 33P-labeled cell walls were extensively extracted with hot sodium dodecyl sulfate (SDS). Of the remaining insoluble radioactivity more than 90% could be released by laminarinase. This radioactive material stayed in the stacking gel during SDS-polyacrylamide gel electrophoresis but entered the separating gel upon treatment with N-glycosidase F, indicating that phosphate was linked directly or indirectly to N-mannosylated glycoproteins. The phosphate was bound to covalently linked cell wall proteins as mannose-6-phosphate, the same type of linkage shown previously for soluble mannoproteins (L. Ballou, L. M. Hernandez, E. Alvarado, and C. E. Ballou, Proc. Natl. Acad. Sci. USA 87:3368-3372, 1990). From the phosphate-labeled glycoprotein fraction released by laminarinase, three cell wall mannoproteins, Ccw12p, Ccw13p and Ccw14p, were isolated and identified by N-terminal sequencing. For Ccw13p (encoded by DAN1 [also called TIR3]) and Ccw12p the association with the cell wall has not been described before; Ccw14p is identical with cell wall protein Icwp (I. Moukadiri, J. Armero, A. Abad, R. Sentandreu, and J. Zueco, J. Bacteriol. 179:2154-2162, 1997). In ccw12, ccw13, or ccw14 single or double mutants neither the amount of radioactive phosphate incorporated into cell wall proteins nor its position in the stacking gel was changed. However, the triple mutant brought about a shift of the 33P-labeled glycoprotein components from the stacking gel into the separating gel. The disruption of CCW12 results in a pronounced sensitivity of the cells to calcofluor white and Congo red. In addition, the ccw12 mutant shows a decrease in mating efficiency and a defect in agglutination.  (+info)

Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. (6/1033)

Our previous studies demonstrated that inhibitors of arachidonate-phospholipid remodeling [i.e. the enzyme CoA-independent transacylase (CoA-IT)] decrease cell proliferation and induce apoptosis in neoplastic cells. The goal of the current study was to elucidate the molecular events associated with arachidonate-phospholipid remodeling that influence cell proliferation and survival. Initial experiments revealed the essential nature of cellular arachidonate to the signaling process by demonstrating that HL-60 cells depleted of arachidonate were more resistant to apoptosis induced by CoA-IT inhibition. In cells treated with CoA-IT inhibitors a marked increase in free arachidonic acid and AA-containing triglycerides were measured. TG enrichment was likely due to acylation of arachidonic acid into diglycerides and triglycerides via de novo glycerolipid biosynthesis. To determine the potential of free fatty acids to affect cell proliferation, HL-60 cells were incubated with varying concentrations of free fatty acids; exogenously provided 20-carbon polyunsaturated fatty acids caused a dose-dependent inhibition of cell proliferation, whereas oleic acid was without effect. Blocking 5-lipoxygenase or cyclooxygenases had no effect on the inhibition of cell proliferation induced by arachidonic acid or CoA-IT inhibitors. An increase in cell-associated ceramides (mainly in the 16:0-ceramide fraction) was measured in cells exposed to free arachidonic acid or to CoA-IT inhibitors. This study, in conjunction with other recent studies, suggests that perturbations in the control of cellular arachidonic acid levels affect cell proliferation and survival.  (+info)

Saccharomyces cerevisiae mid2p is a potential cell wall stress sensor and upstream activator of the PKC1-MPK1 cell integrity pathway. (7/1033)

The MID2 gene of Saccharomyces cerevisiae encodes a protein with structural features indicative of a plasma membrane-associated cell wall sensor. MID2 was isolated as a multicopy activator of the Skn7p transcription factor. Deletion of MID2 causes resistance to calcofluor white, diminished production of stress-induced cell wall chitin under a variety of conditions, and changes in growth rate and viability in a number of different cell wall biosynthesis mutants. Overexpression of MID2 causes hyperaccumulation of chitin and increased sensitivity to calcofluor white. alpha-Factor hypersensitivity of mid2Delta mutants can be suppressed by overexpression of upstream elements of the cell integrity pathway, including PKC1, RHO1, WSC1, and WSC2. Mid2p and Wsc1p appear to have overlapping roles in maintaining cell integrity since mid2Delta wsc1Delta mutants are inviable on medium that does not contain osmotic support. A role for MID2 in the cell integrity pathway is further supported by the finding that MID2 is required for induction of Mpk1p tyrosine phosphorylation during exposure to alpha-factor, calcofluor white, or high temperature. Our data are consistent with a role for Mid2p in sensing cell wall stress and in activation of a response that includes both increased chitin synthesis and the Mpk1p mitogen-activated protein kinase cell integrity pathway. In addition, we have identified an open reading frame, MTL1, which encodes a protein with both structural and functional similarity to Mid2p.  (+info)

Chs7p, a new protein involved in the control of protein export from the endoplasmic reticulum that is specifically engaged in the regulation of chitin synthesis in Saccharomyces cerevisiae. (8/1033)

The Saccharomyces cerevisiae CHS7 gene encodes an integral membrane protein located in the ER which is directly involved in chitin synthesis through the regulation of chitin synthase III (CSIII) activity. In the absence of CHS7 product, Chs3p, but not other secreted proteins, is retained in the ER, leading to a severe defect in CSIII activity and consequently, to a reduced rate of chitin synthesis. In addition, chs7 null mutants show the yeast phenotypes associated with a lack of chitin: reduced mating efficiency and lack of the chitosan ascospore layer, clear indications of Chs7p function throughout the S. cerevisiae biological cycle. CHS3 overexpression does not lead to increased levels of CSIII because the Chs3p excess is retained in the ER. However, joint overexpression of CHS3 and CHS7 increases the export of Chs3p from the ER and this is accompanied by a concomitant increase in CSIII activity, indicating that the amount of Chs7p is a limiting factor for CSIII activity. Accordingly, CHS7 transcription is increased when elevated amounts of chitin synthesis are detected. These results show that Chs7p forms part of a new mechanism specifically involved in Chs3p export from the ER and consequently, in the regulation of CSIII activity.  (+info)

Sodium 5-methoxy-2-methyl-4-(3-oxobutanamido)benzenesulfonate 133167-77-8 NMR spectrum, Sodium 5-methoxy-2-methyl-4-(3-oxobutanamido)benzenesulfonate H-NMR spectral analysis, Sodium 5-methoxy-2-methyl-4-(3-oxobutanamido)benzenesulfonate C-NMR spectral analysis ect.
sodium,2,5-bis(methoxycarbonyl)benzenesulfonate 31314-30-4 NMR spectrum, sodium,2,5-bis(methoxycarbonyl)benzenesulfonate H-NMR spectral analysis, sodium,2,5-bis(methoxycarbonyl)benzenesulfonate C-NMR spectral analysis ect.
Surfactants are often used in supramolecular chemistry, due to their ability to self-organize. Surfactant molecules aggregate spontaneously and reversibly to adopt a defined intermolecular arrangement. In this work, general phase behavior, adsorption and association in aqueous mixtures of dodecylammonium chloride, DACl and sodium 4-(1-pentylheptyl)benzenesulfonate, NaDBS, were studied by a combination of techniques including surface tension and conductivity measurements, light scattering and optical microscopy. The strong synergistic properties of the system were brought out with the Regular Solution Theory.Various colloidal objects are observed in wide range of composition: conventional small vesicles, large giant multilamellar or multivesicular vesicles. An excess of NaDBS provides extremely large tubular and elongated multilamellar vesicles. The new catanionic 1:1 complex, dodecylammonium 4-(1-pentylheptyl) benzenesulfonate, formed in the equimolar conditions is a result of intramolecular ...
Sodium benzenesulfonate | C6H5NaO3S | CID 517327 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
Sodium 5-chloro-2-(4-chloro-2-nitrophenoxy)benzenesulfonate/ACM85136034 can be provided in Alfa Chemistry. We are dedicated to provide our customers the best products and services.
Hepatocellular carcinoma (HCC) is the fifth most common neoplasia, In former times, treatment of advanced HCC with conventional antineoplastic drugs did not result in satisfactory outcomes: recently , in this patient population the oral multikinase inhibitor sorafenib has been able to induce a statistically significant improvement of overall survival. .Similarly to other anti-angiogenic drugs employed in other tumour types, also sorafenib seldom induces the dimensional tumour shrinking usually observed with conventional cytotoxic drugs: data gathered from studies carried out with sorafenib and other competitors under development do not report any complete response in HCV-induced HCC.Case presentationAn 84-year old man with a long-lasting history of chronic HCV hepatitis was referred to our Institution for an ultrasonography investigation of a focal hepatic lesion. To better characterize the liver disease and clearly define the diagnosis of the focal hepatic lesion, the patient was hospitalized ...
The mean elimination half-life of sorafenib was approximately 25 to 48 hours. Multiple doses of NEXAVAR for 7 days resulted in a 2.5- to 7-fold accumulation compared to a single dose. Steady-state plasma sorafenib concentrations were achieved within 7 days, with a peak-to-trough ratio of mean concentrations of less than 2. The steady-state concentrations of sorafenib following administration of 400 mg NEXAVAR twice daily were evaluated in DTC, RCC and HCC patients. Patients with DTC have mean steady-state concentrations that are 1.8-fold higher than patients with HCC and 2.3-fold higher than those with RCC. The reason for increased sorafenib concentrations in DTC patients is unknown.. Absorption and Distribution: After administration of NEXAVAR tablets, the mean relative bioavailability was 38-49% when compared to an oral solution. Following oral administration, sorafenib reached peak plasma levels in approximately 3 hours. With a moderate-fat meal (30% fat; 700 calories), bioavailability was ...
The multi-kinase inhibitor sorafenib (tradename Nexavar®, Bayer) has been recently approved by the FDA for the treatment of non-resectable hepatocarcinoma and advanced renal carcinoma.
Background: Traditional systemic chemotherapy does not provide survival benefits in patients with hepatocellular carcinoma (HCC). Molecular targeted therapy shows promise for HCC treatment, however, the duration of effectiveness for targeted therapies is finite and combination therapies offer the potential for improved effectiveness.. Methods: Sorafenib, a multikinase inhibitor, and YC-1, a soluble guanylyl cyclase (sGC) activator, were tested in HCC by proliferation assay, cell cycle analysis and western blot in vitro and orthotopic and ectopic HCC models in vivo.. Results: In vitro, combination of sorafenib and YC-1 synergistically inhibited proliferation and colony formation of HepG2, BEL-7402 and HCCLM3 cells. The combination also induced S cell cycle arrest and apoptosis, as observed by activated PARP and caspase 8. Sorafenib and YC-1 respectively suppressed the expression of phosphorylated STAT3 (p-STAT3) (Y705) in a dose-and time-dependent manner. Combination of sorafenib and YC-1 ...
The multikinase inhibitor and FDA\approved medication dovitinib (Dov) crosses the bloodCbrain barrier and was recently used as single medication application in clinical trials for GB patients with repeated disease. comet assays, and improved Gigabyte cell apoptosis. Pretreatment of Gigabyte cells with Dov (Dov priming) previous to TMZ treatment decreased Gigabyte cell viability self-employed of g53 position. Sequential treatment including Dov priming and switching treatment cycles with TMZ and Dov considerably decreased lengthy\term Gigabyte cell success in MGMT+ individual Gigabyte cells. Our outcomes may possess instant medical ramifications to improve TMZ response in individuals with LIN28+/HMGA2+ Gigabyte, self-employed of their MGMT methylation position. and mouse xenograft research shown a significant advantage in using a mixed treatment of Dov with platinum eagle substances in digestive tract malignancy (Gaur antiproliferative activity in human being endometrial malignancy cells (Eritja ...
PRIMARY OBJECTIVES:. I. The primary endpoint is the response rate (CR+PR) for each stratum of sarcoma patients treated with sorafenib as defined by RECIST.. SECONDARY OBJECTIVES:. I. Progression-free survival (defined as CR + PR + SD, assessed at 3 months or 6 months).. II. Overall survival. III. Pharmacokinetics of sorafenib in this patient population (all sites will participate).. IV. Frequency of B-raf mutations in the patients sarcomas treated as part of this study and correlation with response or resistance to sorafenib (all sites will participate).. V. Ras-raf kinase pathway activation in pre-treatment existing tumor specimens (paraffin section immunohistochemistry; all sites will participate).. VI. At MSKCC only: Pre and post treatment specimen changes in downstream events of ras signaling, specifically inhibition of ERK phosphorylation. Only patients with angiosarcoma and MPNST will undergo biopsy (up to 10 patients).. VII. At MSKCC only: Circulating Endothelial Cells (CECs), ...
PRIMARY OBJECTIVES:. I. The primary endpoint is the response rate (CR+PR) for each stratum of sarcoma patients treated with sorafenib as defined by RECIST.. SECONDARY OBJECTIVES:. I. Progression-free survival (defined as CR + PR + SD, assessed at 3 months or 6 months).. II. Overall survival. III. Pharmacokinetics of sorafenib in this patient population (all sites will participate).. IV. Frequency of B-raf mutations in the patients sarcomas treated as part of this study and correlation with response or resistance to sorafenib (all sites will participate).. V. Ras-raf kinase pathway activation in pre-treatment existing tumor specimens (paraffin section immunohistochemistry; all sites will participate).. VI. At MSKCC only: Pre and post treatment specimen changes in downstream events of ras signaling, specifically inhibition of ERK phosphorylation. Only patients with angiosarcoma and MPNST will undergo biopsy (up to 10 patients).. VII. At MSKCC only: Circulating Endothelial Cells (CECs), ...
Sorafenib is a multikinase inhibitor targeting several serine/threonine and receptor tyrosine kinases. The drug is marketed as Nexavar and is used in the treatment of renal cell carcinoma (Kidney cancer). It is also being studied as treatment in other types of cancer.
Health,...Drug shows potential for patients with specific gene mutations resear...FRIDAY Feb. 1 (HealthDay News) -- The drug sorafenib shows promise in...Previous research has shown that sorafenib -- currently used to treat ...Researchers at the University of Texas M.D. Anderson Cancer Center in ...,Sorafenib,Slows,Growth,of,Some,Leukemias,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Health,...Phase II study finds sorafenib helps reverse disease resistance to ant...FRIDAY Sept. 5 (HealthDay News) -- The drug sorafenib may help re-se...Women with estrogen-receptor or progesterone-receptor positive (ER or ...However the tumor eventually becomes resistant to anti-hormonal drugs...,Drug,Re-Sensitizes,Breast,Tumors,to,Treatment,medicine,medical news today,latest medical news,medical newsletters,current medical news,latest medicine news
Sorafenib is a multikinase inhibitor of Raf-1, B-Raf and VEGFR-2 with IC50 of 6 nM, 22 nM and 90 nM in cell-free assays, respectively.
Learn about the no-cost, support services available for patients taking NEXAVAR (sorafenib). Visit hcp.nexavar-us.com to see full safety and Prescribing Information.
This trial will compare the tolerability and pharmacokinetics of sorafenib alone or in combination with golvatinib as first-line therapy in patients with
Gentaur molecular products has all kinds of products like :search , LCLabs \ Sorafenib, Free Base \ S-8599 for more molecular products just contact us
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of SORANIB - SORAFENIB based in New Delhi, India
WHITE PHARMACEUTICALS - Exporter, Importer, Distributor, Supplier, Trading Company of Soranib - Sorafenib based in New Delhi, India
Oncotarget | https://doi.org/10.18632/oncotarget.6104 Jun Li, Lehua Shi, Xiaofeng Zhang, Bin Sun, Yefa Yang, Naijian Ge, Huiying Liu, Xia Yang, Lei Chen, Haihua Qian, Mengchao Wu, Zhengfeng Yin
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
DI-fusion, le Dépôt institutionnel numérique de lULB, est loutil de référencementde la production scientifique de lULB.Linterface de recherche DI-fusion permet de consulter les publications des chercheurs de lULB et les thèses qui y ont été défendues.
Looking for online definition of calcofluor white stain in the Medical Dictionary? calcofluor white stain explanation free. What is calcofluor white stain? Meaning of calcofluor white stain medical term. What does calcofluor white stain mean?
Recent evidence suggests that the development of castration resistant prostate cancer (CRPCa) is commonly associated with an aberrant, ligand-independent activation of the androgen receptor (AR). A putative mechanism allowing prostate cancer (PCa) cells to grow under low levels of androgens, is the expression of constitutively active, C-terminally truncated AR lacking the AR-ligand binding domain (LBD). Due to the absence of a LBD, these receptors, termed ARΔLBD, are unable to respond to any form of anti-hormonal therapies. In this study we demonstrate that the multikinase inhibitor sorafenib inhibits AR as well as ARΔLBD-signalling in CRPCa cells. This inhibition was paralleled by proteasomal degradation of the AR- and ARΔLBD-molecules. In line with these observations, maximal antiproliferative effects of sorafenib were achieved in AR and ARΔLBD-positive PCa cells. The present findings warrant further investigations on sorafenib as an option for the treatment of advanced AR-positive PCa.
Sorafenib (Nexavar), is a multikinase inhibitor, which has demonstrated both antiproliferative and antiangiogenic properties in vitro and in vivo, inhibiting the activity of targets present in the tumoral cells (c-RAF [proto-oncogene serine/threonine-protein kinase], BRAF, (V600E)BRAF, c-KIT, and FMS-like tyrosine kinase 3) and in tumor vessels (c-RAF, vascular endothelial growth factor receptor [VEGFR]-2, VEGFR-3, and platelet-derived growth factor receptor β). Sorafenib was initially approved for the treatment of hepatocellular carcinoma and advanced renal cell carcinoma. Experimental studies have demonstrated that sorafenib has both antiproliferative and antiangiogenic properties in vitro and in vivo, against thyroid cancer cells. Furthermore, several completed (or ongoing) studies have evaluated the long-term efficacy and tolerability of sorafenib in patients with papillary, follicular and medullary aggressive thyroid cancer. The results of the different studies showed good clinical ...
We hypothesized that 1) increased HT and HFSR were markers for increased response duration in individuals treated with bevacizumab and/or sorafenib; 2) that since these toxicities are likely derived from the activity of bevacizumab and sorafenib, the development of HT would increase the risk of also developing HFSR; and 3) that VEGFR2 genotypic variation may be responsible for alterations in the activity of bevacizumab and/or sorafenib therapy that would manifest in associations with toxicity or clinical outcome following treatment with these agents. The results of the present study confirm a previously published study where HFSR development was noted to be related to PFS in patients with various solid tumors receiving doses of sorafenib between 300-600 mg bid [17], and a small study that HT is related to bevacizumab response [18]. Moreover, those receiving combination therapy with bevacizumab and sorafenib that developed hypertension enjoyed a greater than 5-fold increase in overall survival ...
Looking for online definition of sorafenib in the Medical Dictionary? sorafenib explanation free. What is sorafenib? Meaning of sorafenib medical term. What does sorafenib mean?
This study reports on the efficacy and mechanism of action of the small-molecule multikinase inhibitor foretinib in preclinical models of ovarian cancer metastasis. Our data suggest 4 principal mechanisms for how foretinib inhibits ovarian cancer growth and metastasis. In ovarian cancer cell lines, the inhibitor: (i) blocked activation of c-Met signaling; (ii) reduced proliferation mediated by a G2-M cell-cycle arrest; (iii) induced cell death through a 2-step mechanism in which cells detach followed by a caspase-dependent form of anoikis; and (iv) reduced proliferation, adhesion, migration, and invasion during early tumor development. In mouse models of ovarian cancer metastasis, foretinib reduced tumor burden and metastasis mediated by reduced angiogenesis, proliferation, and increased apoptosis. The multiple activities of foretinib are consistent with the numerous effects that have been attributed to c-Met and angiogenesis in the context of cancer (3).. Foretinib targets c-Met and VEGFR-2 ...
Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamics Volker Wacheck1, Michael Lahn2, Gemma Dickinson3, Wolfgang Füreder4, Renata Meyer4, Susanne Herndlhofer4, Thorsten Füreder1, Georg Dorfner5, Sada Pillay2, Valérie André6, Timothy P Burkholder7, Jacqueline K Akunda8, Leann Flye-Blakemore9, Dirk Van Bockstaele9, Richard F Schlenk10, Wolfgang R Sperr4, Peter Valent4,111Department of Clinical Pharmacology, Medical University of Vienna, Währinger Gürtel, Vienna, Austria; 2Early Oncology Clinical Investigation, Eli Lilly and Company, Indianapolis, IN, USA; 3Department of Pharmacokinetics, Eli Lilly and Company, Erl Wood Research Centre, Windlesham, Surrey, UK; 4Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Währinger Gürtel, Vienna, Austria; 5Eli Lilly GesmbH, Medical Department, Vienna, Austria; 6Department of Statistics, Eli Lilly and
Purpose: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and VEGFR. We conducted a phase I, first-time-in-human, clinical trial using escalating doses of oral foretinib. Primary objectives were to identify a maximum tolerated dose and determine the safety profile of foretinib. Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity. Experimental Design: Patients had histologically confirmed metastatic or unresectable solid tumors for which no standard measures existed. All patients received foretinib orally for 5 consecutive days every 14 days. Dose escalation followed a conventional "3+3" design. Results: Forty patients were treated in eight dose cohorts. The maximum tolerated dose was defined as 3.6 mg/kg, with a maximum administered dose of 4.5 mg/kg. Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase. ...
After eking out marginal benefit to our patients with HCC for several years with predominantly single-agent doxorubicin and other anthracycline use, we noted that the biologic agent sorafenib rose above the fray. Phase 2 trial data with sorafenib required forward-thinking interpretation of clinical data that included very small response rates. Although response rates were low, a provocative clinical benefit potential for sorafenib in HCC led to completion of the first large randomized trial showing a survival benefit of systemic therapy.. The SHARP trial, presented at ASCO 2007 and published in 2008, showed a superior overall survival with sorafenib therapy (10.7 months) versus placebo (7.9 months).. The SHARP trial focused on patients with overall good liver function (based on Child-Pugh class A), as have many of the therapies to date for this malignancy. Most patients had bilirubin below 2.0 mg/dL, albumin greater than 3.5 g/dL, INR ,1.7 and the absence of significant ascites or hepatic ...
1% collagenase for 3 hrs at room temperature and 1. 5 kUml DNase I for the last 5 min in キナーゼ 阻害剤 L 15 medium followed by pipetting. The cell suspension was wa
Bernd Kasper, MD, PhD, professor, Universitätsmedizin Mannheim, Mannheim, discusses imatinib (Gleevac) versus sorafenib (Nexavar) as treatments for patients with sarcoma.
Open-label, multi-center extension treatment protocol to allow access to tivozanib and sorafenib for subjects who have participated on the AV-951-09-301
The IUPHAR/BPS Guide to Pharmacology. sorafenib ligand page. Quantitative data and detailed annnotation of the targets of licensed and experimental drugs.
Just a quick question. Am I right in thinking that ALL current PSPs can be downgraded and/or permanent CFW installed? Thanks.
Sigma-Aldrich offers abstracts and full-text articles by [Youn Kyoung Jeong, Mi-Sook Kim, Ji Young Lee, Eun Ho Kim, Wonwoo Kim, Hunjoo Ha, Jae-Hoon Jeong].
TSAR is a free, digitally delivered art information utility. Every entry is carefully checked with the presenting institutions. Nevertheless, inaccuracies occur. Always try to call the sponsoring institution to check the facts. In our effort to be an increasingly more valuable product, we ask for your comments and suggestions to be emailed to [email protected] ...
The Russian Orthodox Church posed a number of questions to the investigators and the state commission, which have remained unanswered
The article describes an interesting aquarium inhabitant, such as the shrimp Amano. This crustacean has its own unique features of existence, which
Tocidlowski, M. E., .Stoskopf, M. K. (1997). Comparison of sodium polyanetholesulfonate with EDTA and heparin anticoagulants by assessing packed cell volume and blood smear quality of blood from hybrid white bass X striped ba. Journal of Aquatic Animal Health, 9(2), 151-155 ...
Alfa Aesar™ 2-Chloroethyl p-toluenesulfonate, 97% 500g Alfa Aesar™ 2-Chloroethyl p-toluenesulfonate, 97% Chlorot to Chola -Organics
Sumanta Pal, MD of City of Hope, Duarte, CA, discusses the introduction of new data of the new single-agent cabozantinib for advanced renal cell carcinoma. The agent is a dual MET and VEGFR2 inhibitor, and has been assessed in metastatic renal cell carcinoma and other diseases. Dr Pal highlights his involvement in the Phase I trials of cabozantinibs development in renal cell carcinoma, where impressive responses were observed. He proceeds to highlight that most recently, cabozantinib was used in a Phase III METEOR trial comparing it to the agent everolimus (NCT01865747). This study identified an improvement in response rate, overall survival (OS) and progression-free survival (PFS) for patients with advanced renal cell carcinoma. According to Dr Pal, these findings make the agent the optimal second-line choice in patients with metastatic renal cell carcinoma. He further adds that data from the CABOSUN study (NCT01835158), a clinical trial that compared sunitinib and cabozantinib in the front-line
TY - JOUR. T1 - Sorafenib induces autophagy and suppresses activation of human macrophage. AU - Lin, Jiunn Chang. AU - Liu, Chien Liang. AU - Lee, Jie Jen. AU - Liu, Tsan Pai. AU - Ko, Wen Chin. AU - Huang, Yu Chuen. AU - Wu, Chih Hsiung. AU - Chen, Yu Jen. PY - 2013/2. Y1 - 2013/2. N2 - Background Sorafenib, a multi-kinase inhibitor approved for treatment of advanced renal cell carcinoma and other malignancies, has been shown as a modulator for dendritic cells. This study was designed to examine the effects of sorafenib on macrophages, the major ontogeny of innate immunity. Materials and methods Macrophages were derived from sorted CD14+ monocytes of human peripheral blood mononuclear cells. Cell viability and surface antigens were examined by trypan blue analysis. Autophagy was characterized by light microscopy and transmission electron microscopy for morphology, Western blotting for microtubule associated light chain protein 3B (LC-3B) I lipidation, and acridine orange staining for acidic ...
TY - JOUR. T1 - FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib. AU - Hibi, Masaaki. AU - Kaneda, Hiroyasu. AU - Tanizaki, Junko. AU - Sakai, Kazuko. AU - Togashi, Yosuke. AU - Terashima, Masato. AU - De Velasco, Marco Antonio. AU - Fujita, Yoshihiko. AU - Banno, Eri. AU - Nakamura, Yu. AU - Takeda, Masayuki. AU - Ito, Akihiko. AU - Mitsudomi, Tetsuya. AU - Nakagawa, Kazuhiko. AU - Okamoto, Isamu. AU - Nishio, Kazuto. PY - 2016/11/1. Y1 - 2016/11/1. N2 - Fibroblast growth factor receptor (FGFR) gene alterations are relatively frequent in lung squamous cell carcinoma (LSCC) and are a potential targets for therapy with FGFR inhibitors. However, little is known regarding the clinicopathologic features associated with FGFR alterations. The angiokinase inhibitor nintedanib has shown promising activity in clinical trials for non-small cell lung cancer. We have now applied next-generation sequencing (NGS) to characterize FGFR ...
5-AMINO-3-SULFOSALICYLIC ACID | C7H7NO6S | CID 22574 - structure, chemical names, physical and chemical properties, classification, patents, literature, biological activities, safety/hazards/toxicity information, supplier lists, and more.
The present studies sought to further understand how the anti-folate pemetrexed and the multi-kinase inhibitor sorafenib interact to kill tumor cells. end up being activated by ceramide and Place/I2PP2A may end up being inhibited by ceramide directly. Inhibition of the de ceramide synthase path obstructed drug-induced ceramide era novo, PP2A tumor and activation cell eliminating. Jointly these results demonstrate that ERK1/2 has an important function downstream of SRC in pemetrexed and sorafenib lethality and that PP2A has an essential function in controlling this procedure. ERK1/2 (age.g., Flower CHR-6494 IC50 et al., 2010).23 ERK1/2 signaling is generally thought to act as a protective sign against the toxic results of therapeutic real estate agents; real estate agents that activate apoptotic paths. Sorafenib was eventually discovered to hinder multiple RTKs such as SSI-2 platelet-derived development aspect (PDGFR), vascular endothelial development aspect receptors 1 and 2 (VEGFR1 and VEGFR2), ...
TY - JOUR. T1 - Treatment with low-dose sorafenib in combination with a novel benzimidazole derivative bearing a pyrolidine side chain provides synergistic anti-proliferative effects against human liver cancer. AU - Hsu, Ming Hua. AU - Hsu, Shih Ming. AU - Kuo, Yu Cheng. AU - Liu, Chih Yu. AU - Hsieh, Cheng Ying. AU - Twu, Yuh Ching. AU - Wang, Chung Kwe. AU - Wang, Yuan Hsi. AU - Liao, Yi Jen. PY - 2017. Y1 - 2017. N2 - Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies and deadliest cancers in the world. Currently, sorafenib is the only drug that has been approved by the U.S. FDA for patients with advanced HCC. However, its improvement on patient outcomes is modest, and the median survival time is only prolonged 2-3 months. In addition, the application of sorafenib is limited because of its high cost and severe adverse side-effects. Therefore, developing more effective novel agents and reducing the dosage of sorafenib are urgently needed for HCC therapy. Here, a novel ...
The results of a phase III trial comparing two commonly used drugs in the second-line treatment of renal cell carcinoma suggest that temsirolimus does not improve survival over sorafenib in the second line setting.. The two drugs inhibit different targets: temsirolimus targets mTOR, which regulates cell growth and proliferation, while sorafenib inhibits several tyrosine kinases, including VEGF receptors.. This is the first head-to-head phase III trial comparing a VEGF inhibitor to an mTOR inhibitor in renal cell carcinoma, reporting final results. Hence, this trial will have important treatment implications for patients and physicians, noted Dr Thomas Hutson from Texas Oncology-Baylor Charles A Sammons Cancer Center in Texas, USA.. Temsirolimus had demonstrated an overall survival benefit compared to interferon alfa in previously untreated patients with advanced renal cell carcinoma and poor prognostic features, but the drugs efficacy after treatment with a VEGF inhibitor was not known, Dr ...
Several days after starting sorafenib, the patient developed diarrhea, erythematous swelling of finger tips and greyish blisters on the palms of his hands grade 2 according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. These adverse events subsided spontaneously over the next 2 weeks. Eleven days after starting sorafenib (19 days after radiotherapy), the patient complained of erythematous patch with pruritus (dermatitis CTCAE grade 1) in the right seventh anterior rib area. The patient was only taking sorafenib and tenofovir at this time. There were no obvious signs of infection (fever, pain, swelling, or warmth). White blood cell count was normal (10,000/μL). C-reactive protein level was mildly elevated (2.62 mg/dL; normal range, 0.00 to 0.30 mg/dL). When assessed by radiation oncology 20 days after starting sorafenib (28 days after radiotherapy), there was patchy erythematous hyperpigmentation and dry desquamation (dermatitis CTCAE grade 1) in the area, ...
Blood cultures are among the most important tests used for the diagnosis of infectious diseases; they are commonly ordered and detect a wide variety of microbes, and the results are usually clinically relevant. The use of PCR for the detection and identification of microbes in blood cultures has been rather limited to date (11,13, 18, 19), despite certain theoretical advantages to sequence-based identification, such as the speed and the specificity of identification. In some of the studies from which successful bacterial DNA amplification was reported, SPS-free blood culture medium was used for PCR, such as noncommercial broth (13) or BACTEC 12B mycobacterial medium (11). In another study, BACTEC 13A medium containing SPS was used, and the presence of a PCR inhibitor was noted after phenol-chloroform extraction of the samples, but the inhibitor was not identified (18). Those investigators did have success in amplifying mycobacterial DNA from blood cultures by using a combination of washing of ...
0097]The compounds of this invention include the compounds themselves, as well as their salts, solvate, hydrate, polymorph, or prodrugs, if applicable. As used herein, the term "pharmaceutically acceptable salt," is a salt formed from, for example, an acid and a basic group of a compound of any one of the formulae disclosed herein. Illustrative salts include, but are not limited, to sulfate, citrate, acetate, chloride, bromide, iodide, nitrate, bisulfate, phosphate, acid phosphate, lactate, salicylate, acid citrate, tartrate, oleate, tannate, pantothenate, bitartrate, ascorbate, succinate, maleate, besylate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, and p-toluenesulfonate salts. The term "pharmaceutically acceptable salt" also refers to a salt prepared from a compound of any one of the formulae disclosed herein having an acidic functional group, such as a carboxylic acid functional group, and a ...
Results: Sunitinib and sorafenib display direct antiproliferative effects against cancer cells at concentrations that may be obtained in the clinic with IC50s ranging 1.8 -12.0 µM and 4.2-13.8 µM, respectively. The cytotoxicity profile of sunitinib was distinct from sorafenib with cross-resistance/sensistivity in only a limited number of cell lines. Sunitinib appears at least 2-fold more potent than sorafenib in hepatocellular and Head&Neck carcinoma cells. Interestingly, imatinib (IC50 ranging 11.5-38.2 µM) was consistently less potent than sunitinib and sorafenib in blocking cell proliferation suggesting that sunitinib- and sorafenib-mediated antiproliferative effects may not be due to PDGFR inhibition. Consistently, no correlation between sunitinib/sorafenib antiproliferative effects and the levels of PDGFR A&B expression was detectable. Among other potential target tyrosine kinases, we investigated the levels of expression of VEGFR 1-3 and although most cells expressed VEGFRs, we found no ...
People who have advanced HCC or are on a medical trial may be supplied a targeted therapy drug. Tiangong sighed We will solely hope that Qin Mu remains to be rational, not to be controlled Provide Low cost nexavar male enhancement Drugs Feature Tales by his brother. Cancer medication can interact with another medicines and herbal merchandise. All patients had been to have one comply with-up go to approximately 30 days after the final dose of linifanib or sorafenib ...
FRANKFURT Tue Mar 11, 2014 4:22am EDT. (Reuters) - Germanys Bayer said a final stage Phase III clinical trial of cancer drug Nexavar as an adjuvant therapy for liver cancer did not meet its main target.. Nexavar, or sorafenib, is made by Bayer and Onyx Pharmaceuticals, and is already approved to treat advanced kidney cancer and liver cancer that cannot be surgically removed.. Bayer is testing the drug, taken orally, as an additional treatment for liver cancer patients who had no detectable disease after surgery. It said on Tuesday that the trial did not meet its main goal of improving recurrence-free survival.. We are disappointed that the trial did not meet its primary endpoint, said Joerg Moeller, member of the Bayer HealthCare Executive Committee. However, we remain committed to exploring the full potential of sorafenib in all stages of liver cancer.. Bayer shares were down 0.3 percent in early trade, underperforming a 0.2 percent rise for German blue chips.. Liver cancer is the sixth ...
The lack or complexity of high resolution technologies and the need for labelled compound derivatives represents a major limitation on the study of intracellular distribution dynamics of pharmacological agents. The intrinsic, label-free and organelle-specific fluorescence activity of nintedanib presented in this study provides a powerful tool to dissect intracellular accumulation and distribution dynamics of this clinically approved small molecule TKI. The observation that lysosomal alkalization via V-ATPase inhibition sensitized lung cancer cells towards nintedanib suggests that protonation-based lysosomal sequestration represents a cell-intrinsic protection mechanism against this FGFR inhibitor. In accordance, various chemotherapeutic agents including doxorubicin, mitoxantrone and vincristine but also TKIs such as gefitinib, lapatinib and sunitinib have been reported to be subject to inactivating lysosomal sequestration [23, 30]. Together, these findings support a yet underestimated central ...
An equilibrium between 62-reliant self-renewal and canonical Wnt signaling-directed commitment regulates mammalian nephrogenesis. to changeover to epithelial renal vesicles (RVs), each TAK-375 RV offering rise to an individual nephron (Carroll et al., 2005). Progenitors located next to the medullary encounter of branch ideas cluster to create pretubular aggregates before transitioning to epithelial RVs whereas those in the outermost kidney cortex remain undifferentiated. Significantly, the maintenance of CM progenitors ensures continuing ureteric branching through the creation of branching elements, and the mobile template for brand-new waves of nephrogenesis before progenitor population is certainly tired in the prenatal or early postnatal period. Nephron progenitors exhibit the transcriptional regulator Six2 (Kobayashi et al., 2008). The Six2+ inhabitants comprises self-renewing, multi-potent nephron progenitors, and Six2 is vital for preserving the progenitor condition; CM prematurely goes ...
CiteSeerX - Scientific documents that cite the following paper: Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol 2007;37:755-62
RATIONALE: Sorafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizum
Treatment of patients with the VEGFR TKIs sorafenib and sunitinib can lead to periods of tumor stability, but resistance to therapy is inevitable. We used a mouse model to define mechanisms by which resistance develops and found that components of the IFNγ signaling pathway are lost with sunitinib or sorafenib therapy. Our data also show that CXCL9 treatment delays resistance to sunitinib in 786-O- and A498-derived tumors and that one mechanism by which this occurs is by prolongation of the antiangiogenic effects of sunitinib. These data suggest that angiostatic pathways are suppressed as a result of VEGFR TKI therapy and set the stage for the subsequent development of resistance to therapy.. In the setting of VEGFR inhibition, RCC tumors undergo extensive necrosis (22). In the setting of this necrosis and accompanying hypoxia/nutrient deprivation, tumors may undergo compensatory changes, including the induction of salvage angiogenesis pathways. We propose that the environmental stress ...
The goal of this clinical research study is to learn the most tolerable dose of Nexavarâ (sorafenib) when given in combination with Mobozilâ (plerixafor) and Neupogenâ (filgrastim) to patients with AML. The safety of this combination will also be studied.
Flumatinib is a multi-kinase inhibitor with IC50 Values of 1.2 nM, 307.6 nM and 2662 nM for c-Abl, PDGFRβ and c-Kit respectively. ...Quality confirmed by NMR,HPLC & MS.
Affiliation:大阪医科大学,医学部,講師, Research Field:Ophthalmology,Rehabilitation science/Welfare engineering, Keywords:緑内障,濾過手術,濾過胞,視神経挫滅モデル,ハイドロゲル,NAD,サーチュイン,徐放,視神経乳頭循環,眼圧, # of Research Projects:6, # of Research Products:19, Ongoing Project:Effect of a multikinase inhibitor on glaucoma surgery model
The Phase II SHARP (Sorafenib HCC Assessment Randomized Protocol) trial by Josep M. Llovet, MD, is the most significant study looking at the targeted agent in this disease, Dr. Abou-Alfa said. The 602 patients included in the study were randomized to 400 mg of sorafenib twice daily or placebo.. The primary endpoints were overall survival and time to symptomatic progression. Median survival was 10.7 months with sorafenib vs 7.9 months for placebo.. "Clinically, this was significant enough to have the FDA approve the drug as a standard of care for unresected HCC, so we have a standard of care and this should be used as such," he said.. The best thing about the SHARP study is that the patients included in the trial-about 33% of whom had hepatitis C; 20%, hepatitis B; and 25%, alcohol-related problems-are the patients oncologists actually see in the clinic, he said.. In a retrospective analysis of 500 patients at MSKCC, one-third had hepatitis C, and another third alcohol abuse. There were slightly ...
Nexavar, a drug co-developed by Bayer HealthCare Pharmaceuticals Inc. and U.S. drugmaker Onyx Pharmaceuticals, Inc., has failed to meet its primary endpoint in a late-stage study evaluating its potential in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer, the companies said Tuesday.
The drug pazopanib (Votrient) slowed the progression of advanced renal cell carcinoma, a form of kidney cancer, in patients by 54 percent, according to a new study published in the Journal of Clinical Oncology.
Drug Czar Ramstad? Now that the State and Treasury department picks have been officially unveiled, the parlor game of Obama cabinet speculation turns to the less high-profile posts - the people...
We describe a case of acute liver failure in a patient with advanced hepatocellular carcinoma related to nonalcoholic steatohepatitis during sorafenib treatment. A 74-year-old man with diabetes mellitus and hypertension was diagnosed with hepatocellular carcinoma associated with fatty liver. Three weeks after sorafenib therapy, at Eastern Cooperative Oncology Group performance status 3, he developed jaundice, general weakness, flapping tremor, nausea, and anorexia. Sorafenib was stopped: laboratory tests showed a relevant elevation of transaminases suggesting diagnosis of acute hepatitis. During hospital admission, the patient died of liver failure. Sorafenib is the first successful target therapy effective for advanced hepatocellular carcinoma. The most common adverse events are fatigue, hand-foot skin reaction, skin rash/desquamation, diarrhea, and hypertension, whereas liver dysfunction is uncommon. To our knowledge, this is the first patient reported in the literature with hepatocellular ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. HTF Market Intelligence released a new research report of 108 pages on title Global Sulfosalicylic Acid Sodium Salt Sales Market Report 2017′ with detailed analysis, forecast and strategies.. Summary. In this report, the global Sulfosalicylic Acid Sodium Salt market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.. Request a sample report @ https://www.htfmarketreport.com/sample-report/269645-global-sulfosalicylic-acid-sodium-salt-sales-market. Report Highlights. Geographically, this report split global into several key Regions, with sales (volume), revenue (value), market share and growth rate of Sulfosalicylic Acid Sodium Salt for these regions, from 2012 to 2022 (forecast), covering. United States. China. Europe. Japan. Southeast Asia. India. Buy this report @ ...
Headline: Bitcoin & Blockchain Searches Exceed Trump! Blockchain Stocks Are Next!. Metastatic Renal Cell Carcinoma market report covers research informatics related to Metastatic Renal Cell Carcinoma clinical trials, such as a listing of industry and sponsored clinical trials as well as new drug therapies.. Designed to be a resource both for patients interested in participating in Metastatic Renal Cell Carcinoma clinical trials and for research professionals.. The report, "Metastatic Renal Cell Carcinoma Global Clinical Trials Review, H2, 2016″ provides an overview of Metastatic Renal Cell Carcinoma clinical trials scenario. This report provides top line data relating to the clinical trials on Metastatic Renal Cell Carcinoma. Report includes an overview of trial numbers and their average enrolment in top countries conducted across the globe. The report also offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.. Browse ...
RATIONALE: Sorafenib and erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sorafenib may also stop the growth of non-small cell lung cancer by blocking blood flow to the tumor. Giving sorafenib together with erlotinib may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving sorafenib together with erlotinib works in treating patients with stage IIIB or stage IV non-small cell lung cancer that has not responded to chemotherapy.
The bevacizumab experience in advanced renal cell carcinoma Lauren C Harshman, Sandy SrinivasDivision of Oncology, Stanford University School of Medicine, Stanford, California, USAAbstract: Bevacizumab in combination with interferon alfa is now approved for treatment-naïve advanced renal cell carcinoma (RCC) in both the US and Europe. Its objective response rates of 30% and progression-free survival rates of 9–10 months are ­comparable to the other approved first-line multityrosine kinase inhibitors, sunitinib and pazopanib. Its advantages include a different toxicity profile and assurance of ­administration compliance given its intravenous formulation. Enthusiasm for its use is blunted by the increased costs, the potential infusion-related reactions, the associated interferon-related toxicities, and the inconvenience of its nonoral formulation. Further study is warranted to assess its efficacy both as a single agent and in combination with the targeted agents and other
TY - JOUR. T1 - Multicellular spheroids from normal and neoplastic thyroid tissues as a suitable model to test the effects of multikinase inhibitors. AU - Cirello, Valentina. AU - Vaira, Valentina. AU - Grassi, Elisa Stellaria. AU - Vezzoli, Valeria. AU - Ricca, Dario. AU - Colombo, Carla. AU - Bosari, Silvano. AU - Vicentini, Leonardo. AU - Persani, Luca. AU - Ferrero, Stefano. AU - Fugazzola, Laura. PY - 2017/2/7. Y1 - 2017/2/7. N2 - Multicellular three-dimensional (3D) spheroids represent an experimental model that is intermediate in its complexity between monolayer cultures and patients tumor. In the present study, we characterize multicellular spheroids from papillary (PTC) and follicular (FTC) thyroid cancers and from the corresponding normal tissues. We show that these 3D structures well recapitulate the features of the original tissues, in either the differentiated and "stem-like" components. As a second step, we were aimed to test the effects of a small multikinase inhibitor, SP600125 ...
Interim results from a randomized clinical trial for patients with desmoid tumors or aggressive fibromatosis show that the drug sorafenib tosylate (Nexavar) extended progression-free survival compared with a placebo. Based on these interim results, the data and safety monitoring board overseeing the trial recommended that the primary results of the study be released.. The trial was sponsored by the NCI, designed and conducted by the Alliance for Clinical Trials in Oncology, and supported by Bayer HealthCare AG, which provided the study drug.. Sorafenib is approved by FDA for the treatment of some patients with advanced kidney, liver, and thyroid cancer. The drug was chosen for this trial because in earlier retrospective studies of patients treated with sorafenib, desmoid tumors shrank, and patients had a reduction in pain and other symptoms.. The phase III double-blind clinical trial, designated as A091105, enrolled 87 patients with DT/DF between March 2014 and December 2016. To be eligible, ...
In metastatic renal cell carcinoma (mRCC), many factors influence clinical decisions, including histology, tumour burden, prognostic factors, comorbidities, and the ability of the patient to tolerate treatment. Progression-free survival (PFS) durations reported from randomized trials of targeted therapies vary considerably, in part because of differences in patient characteristics. For first-line therapy, an estimate of PFS with sunitinib, bevacizumab plus interferon, or sorafenib in a general population is 8-9 months, but each regimen is suitable for different patient categories. For example, sunitinib is suitable for all-prognosis groups, particularly younger, fitter patients; pazopanib for patients with a good or intermediate prognosis; bevacizumab plus interferon for good-prognosis patients or those with indolent disease; and sorafenib for patients at all prognostic risk levels, particularly the elderly and those with comorbidities. Sequential therapy with targeted agents provides ...
Nexavar is an orally active, multi-kinase inhibitor approved by the U.S. Food and Drug Administration (FDA) for the treatment of advanced renal cell carcinoma.
Myeloid sarcoma of the breast is a rare manifestation of acute myeloid leukaemia (AML). This report describes a patient who was diagnosed with AML FAB M2. Molecular analysis showed evidence of an NPM1 mutation (subtype A) and internal tandem duplications of the FLT3 gene (FLT3-ITD). Eight months after allogeneic stem cell transplantation, the patient developed a palpable mass in the left breast initially suspected as breast carcinoma. Core needle biopsy of the lesion resulted in diagnosis of myeloid sarcoma. Molecular analysis of formalin-fixed specimens of the breast tumour confirmed the known FLT3 and NPM1 gene mutations. Immunohistochemically, an aberrant cytoplasmic staining pattern for NPM1 and overexpression of FLT3 were demonstrated. The myeloid sarcoma showed complete transient resolution following treatment with the kinase inhibitor sorafenib. However, the patient developed bone marrow relapse and died in fatal cerebral haemorrhage 1 year after initial diagnosis of AML. In summary, ...
In one study, viagra pills price in india 280 women and men between 60 and 79 years were given DHEA (50 mg) or placebo daily for a year? Lisinopril (Prinivil, lady era canada Zestril) is an ACE inhibitor used to treat high blood pressure, and in combination with other medications to treat heart failure? The Supreme Court explicitly cautioned that the Daubert list should not be regarded by judges as "a definitive checklist or test" Yet in practice, judges have judged the admissibility of scientific evidence using the "Daubert factors" as a checklist; for example, the trial court judge in Kumho admitted to erroneously treating the factors as mandatory! Treatment should be initiated, cyclosporine eye drops price however, to reduce the potential for spreading the infection? , cyclosporine eye drops price maleate, gentisinate, fumarate, gluconate, glucaronate, saccharate, formate, benzoate, glutamate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate andpalmoate [ie, 1,1- ...
On April 19, the FDA approved pembrolizumab (Keytruda, Merck & Co. Inc.) plus axitinib (Inlyta, Pfizer Inc.) for the first-line treatment of patients with advanced renal cell carcinoma (RCC ...
On December 13, the U.S. Food and Drug Administration (FDA) accepted a supplemental Biologics License Application (sBLA) for priority review of nivolumab (Opdivo) plus ipilimumab (Yervoy) to treat intermediate- and poor-risk patients with advanced renal cell carcinoma. The FDA also previously granted Breakthrough Therapy designation for this application-the second indication for which the combination of nivolumab and ipilimumab has received this designation. The application is based on data from the phase III CheckMate-214 study, which was stopped early based on the recommendation of an independent data monitoring committee following a planned interim analysis of overall survival. The results of the study were recently presented by Escudier et al at the European Society for Medical Oncology 2017 Congress (Abstract LBA5).. The application has an action date of April 16, 2018.. About CheckMate-214. CheckMate-214 is a phase III, randomized, open-label study evaluating the combination of nivolumab ...
Medical oncologist Robert Motzer discusses significant treatment advances and improved prognosis for patients with advanced renal cell carcinoma.
In collaboration with the Food and Drug Administration (FDA), and as a service to our members, ATA will provide updates on recent FDA approvals and other important FDA actions (e.g., updated safety information, new prescribing information) pertaining to therapies for cancer patients. This will allow the agency to inform oncologists and professionals in oncology-related fields in a timely manner. Included in the email from the FDA will be a link to the product label or to other sites for additional relevant clinical information. The following is a message from the FDAs Office of Hematology and Oncology Products Director, Dr. Richard Pazdur:. On November 22, 2013, the U. S. Food and Drug Administration approved sorafenib (NEXAVAR® tablets, Bayer Healthcare Pharmaceuticals Inc.) for the treatment of locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment. Sorafenib was previously approved for treatment of renal cell carcinoma ...
AM0010, alone or in combination with immune checkpoint inhibitors, shows high and durable clinical responses in patients with advanced renal cell carcinoma.
List of Tables. Number of Products under Development for Metastatic Renal Cell Carcinoma, H1 2015 12. Number of Products under Development for Metastatic Renal Cell Carcinoma-Comparative Analysis, H1 2015 13. Number of Products under Development by Companies, H1 2015 15. Number of Products under Development by Companies, H1 2015 (Contd..1) 16. Number of Products under Development by Companies, H1 2015 (Contd..2) 17. Number of Products under Investigation by Universities/Institutes, H1 2015 18. Comparative Analysis by Late Stage Development, H1 2015 19. Comparative Analysis by Clinical Stage Development, H1 2015 20. Comparative Analysis by Early Stage Development, H1 2015 21. Comparative Analysis by Unknown Stage Development, H1 2015 22. Products under Development by Companies, H1 2015 23. Products under Development by Companies, H1 2015 (Contd..1) 24. Products under Development by Companies, H1 2015 (Contd..2) 25. Products under Investigation by Universities/Institutes, H1 2015 26. Metastatic ...
BACKGROUND: Previous studies combining PD-1 checkpoint inhibitors with tyrosine kinase inhibitors of the VEGF pathway have been characterised by excess toxicity, precluding further development. We hypothesised that axitinib, a more selective VEGF inhibitor than others previously tested, could be combined safely with pembrolizumab (anti-PD-1) and yield antitumour activity in patients with treatment-naive advanced renal cell carcinoma. METHODS: In this ongoing, open-label, phase 1b study, which was done at ten centres in the USA, we enrolled patients aged 18 years or older who had advanced renal cell carcinoma (predominantly clear cell subtype) with their primary tumour resected, and at least one measureable lesion, Eastern Cooperative Oncology Group performance status 0-1, controlled hypertension, and no previous systemic therapy for renal cell carcinoma ...
MnTE-2-PyP, a superoxide dismutase mimetic, inhibited OVA-induced airway inflammation in mice suggesting an impact in Th2 responsiveness. on immature DC. Our research claim that the main mechanism where MnTE-2-PyP inhibits airway irritation is normally by functioning on the DC and suppressing Th2 cell proliferation and activation. allergen provocation is normally elevated in asthmatics [6]. Furthermore, asthmatic sufferers demonstrate depressed degrees of endogenous antioxidant immune system such as for example superoxide dismutase (SOD) and glutathione [7]. Our lab is rolling out a SOD mimetic, MnTE-2-PyP [chemical substance name: Manganese (III) with MnTE-2-PyP demonstrated a reduced capability to support T cell proliferation, recommending an inhibitory function of MnTE-2-PyP on APC function [17]. Tse < 0.01) separate of OVA323C339 peptide concentrations when the SOD mimetic was within the culture mass media. Amount 2 MnTE-2-PyP inhibits Th2 cell proliferation. Th2 and DC cells were ...
In this case-based interview series, Anthony El-Khoueiry, MD, outlines the most important factors to consider in advanced hepatocellular carcinoma and discusses treatment options in patients who have progressed following therapy with sorafenib.
Nivolumab versus Cabozantinib: Comparing Overall Survival in Metastatic Renal Cell Carcinoma. . Biblioteca virtual para leer y descargar libros, documentos, trabajos y tesis universitarias en PDF. Material universiario, documentación y tareas realizadas por universitarios en nuestra biblioteca. Para descargar gratis y para leer online.
Comparing the Relative Importance of Attributes of Metastatic Renal Cell Carcinoma Treatments to Patients and Physicians in the United States: A Discrete-Choice Experiment.
COA of Sorafenib Tosylate contains the actual results obtained from testing performed as part of quality control. View our Sorafenib Tosylate specific physical and chemical properties, and analytical data.
Axel Merseburger, from the Schleswig-Holstein University Hospital, Lübeck, Germany, discusses the joint meeting of the EAU and Japanese Urological Association at the European Association of Urology (EAU) conference 2017 in London, UK. European and Japanes uro-oncologists discussed the best second-line treatment in advance metastatic renal cell carcinoma (RCC).
The FDA today approved the combination of nivolumab and ipilimumab for the treatment of intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma.The FDA based this decision on data from 847 intermediate- or poor-risk patients with previously untreated advanced renal cell carcinoma from the randomized open-label CheckMate-214 trial, which compared the combination
TY - JOUR. T1 - Systemic cytotoxic chemotherapy of patients with advanced hepatocellular carcinoma in the era of sorafenib nonavailability. AU - Yoon, Eileen L.. AU - Yeon, Jong Eun. AU - Lee, Hyun Jung. AU - Suh, Sang Jun. AU - Lee, Sun Jae. AU - Kang, Seong Hee. AU - Kang, Keunhee. AU - Yoo, Yang Jae. AU - Kim, Ji Hoon. AU - Yim, Hyung Joon. AU - Byun, Kwan Soo. PY - 2014/3/1. Y1 - 2014/3/1. N2 - GOALS:: The goal of the study was to compare the efficacy and safety of sorafenib with those of systemic cytotoxic chemotherapy. BACKGROUND:: Sorafenib treatment has shown to improve the survival in patients with advanced hepatocellular carcinoma (HCC) when compared with placebo. However, whether sorafenib controls advanced-stage HCC better than systemic cytotoxic chemotherapy has not been elucidated. STUDY:: We retrospectively reviewed the medical records of 220 patients with measurable advanced HCC who had not received systemic treatment previously between January 2007 and April 2012. Among these ...
The purpose was to assess the cost-effectiveness of sorafenib in the treatment of hepatocellular carcinoma (HCC) patients incorporating current prices and the results of the recent published field practice SOraFenib Italian Assessment (SOFIA) study. We created a Markov Decision Model to evaluate, in a hypothetical cohort of Caucasian male patients, aged 67 years with Barcelona Clinic Liver Cancer (BCLC) C HCC, or BCLC B HCC who were unfit or failed to respond to locoregional therapies, well compensated cirrhosis, and with performance status 0-1 according to Eastern Cooperative Oncology Group (ECOG), the cost-effectiveness of the following strategies: (1) full or dose-adjusted sorafenib for BCLC B and C patients together; (2) full or dose-adjusted sorafenib for BCLC B patients; (3) full or dose-adjusted sorafenib for BCLC C patients. Outcomes include quality-adjusted life years (QALYs), costs, and incremental cost-effectiveness ratio (ICER). In the base-case analysis dose-adjusted sorafenib was ...
Take Home Message The European Association of Urology renal cancer guidelines panel recommends nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of vascular endothelial growth factor-targeted therapy. New data have recently become available showing a survival benefit for cabozantinib. Keywords: Nivolumab, Cabozantinib, Renal cancer, Guidelines, European Association of Urology. Footnotes a The Royal Free NHS Trust and Barts Cancer Institute, Queen Mary University of London, London, UK b Department of Urology, Ludwig-Maximilians University, Munich, Germany c Department of Surgical and Perioperative Sciences, Urology and Andrology, Umeå University, Umeå, Sweden d Department of Urology, University of Rennes, Rennes, France e Division of Urology, University of Texas Medical School at Houston, Houston, TX, USA f Department of Urology, Skåne University Hospital, Malmö, Sweden g Patient Advocate International Kidney Cancer Coalition (IKCC),
AGEP is characterized by numerous, small, non-follicular and sterile pustules arising within extensive areas of edematous erythema. Fever and leukocytosis are common findings and severe cases of AGEP can associate visceral involvement. Mucous membrane might also be affected. Time interval between drug administration and the skin eruption onset is typically 48h, although it varies from 1 day to 4 weeks. It typically resolves in two weeks after drug discontinuation.1,2 Main differential diagnoses of AGEP are other pustular diseases, such as pustular psoriasis, and other severe cutaneous adverse reactions, such as Stevens Johnson syndrome (SJS) or Toxic Epidermal Necrolysis. Compared to AGEP, in SJS/NET, mucosal involvement and skin detachment (Nikolsky sign) are a constant. However, the possibility of overlap of different severe cutaneous reactions have been recently discussed in the literature.3. Sorafenib is a multikinase inhibitor that mainly target tumor cell angiogenesis, first used in ...
The treatment of metastatic renal cell carcinoma (RCC) has changed dramatically over the past few years. An improved understanding of the biology of RCC has resulted in the development of novel targeted therapeutic agents that have altered the natural history of this disease. In particular, the hypoxia-inducible factor (HIF)/vascular endothelial growth factor (VEGF) pathway and the mammalian target of rapamycin (mTOR) signal transduction pathway have been exploited. Sunitinib malate (Sutent), sorafenib tosylate (Nexavar), bevacizumab (Avastin)/interferon alfa, and temsirolimus (Torisel) have improved clinical outcomes in randomized trials by inhibiting these tumorigenic pathways. Combinations and sequences of these agents are being evaluated. Other novel multitargeted tyrosine kinase inhibitors (pazopanib and axitinib) and mTOR inhibitors (everolimus) are in clinical development. Recently reported and ongoing clinical trials will help further define the role of these agents as therapy for metastatic RCC
Title:Glutathione for Hepatotoxicity in Patients with Liver Cirrhosis and Advanced Hepatocellular Carcinoma Receiving Hepatic Arterial Infusion Chemotherapy. VOLUME: 2 ISSUE: 1. Author(s):Koichi Momiyama, Hidenari Nagai, Yu Ogino, Takanori Mukozu, Daigo Matsui, Teppei Matsui, Noritaka Wakui, Mie Shinohara, Yoshinori Igarashi and Yasukiyo Sumino. Affiliation:Division of Gastroenterology and Hepatology, Department of Internal Medicine (Omori), School of Medicine, Faculty of Medicine, Toho University, 6-11-1, Omorinishi, Otaku, Tokyo, Japan, 143-8541.. Keywords:5-FU, HCC, hepatic arterial infusion chemotherapy, hepatotoxicity, liver fibrosis, glutathione, 7S domain of type IV collagen, hyaluronic acid, N-terminal propeptide of type III procollagen.. Abstract:Purpose: We have previously reported that hepatic arterial infusion chemotherapy (HAIC) prolongs the survival of patients with advanced hepatocellular carcinoma (aHCC). However, 5- fluorouracil (5-FU) has been found to exacerbate liver damage ...

SurfactantsSurfactants

Linear Alkyl Benzene Sulfonates. Normal alpha olefins react with benzene via Lewis acid catalysis to form linear alkyl benzenes ... LABs). Sulfonation and subsequent neutralization of LAB result in linear alkyl benzene sulfonates, which are commonly used in ...
more infohttp://www.cpchem.com/bl/nao/en-us/Pages/Surfactants.aspx

Introduction of Polymer additives | Chemical Products|ADEKAIntroduction of Polymer additives | Chemical Products|ADEKA

Anionic Surfactants: Alkyl Sulfonates, Alkyl Benzene Sulfonates, etc.. Antistatic capabilities of these surfactants are ...
more infohttps://www.adeka.co.jp/en/chemical/products/plastic/knowledge_04.html

Molecular mechanisms of band 3 inhibitors. 3. Translocation inhibitors.Molecular mechanisms of band 3 inhibitors. 3. Translocation inhibitors.

Benzenesulfonates / pharmacology*. Biological Transport, Active / drug effects. Chlorides / blood*. Dinitrofluorobenzene / ... 0/Anion Exchange Protein 1, Erythrocyte; 0/Benzenesulfonates; 0/Chlorides; 0/NBD-taurine; 0/Nicotinic Acids; 0/Oxadiazoles; ...
more infohttp://www.biomedsearch.com/nih/Molecular-mechanisms-band-3-inhibitors/3801448.html

Patent US20060019332 - Deparaffinization compositions for dewaxing tissue specimens - Google PatentsPatent US20060019332 - Deparaffinization compositions for dewaxing tissue specimens - Google Patents

... sodium or potassium alkyl benzene sulfonates; sodium alkyl glyceryl ether sulfonates; sodium coconut oil fatty acid ...
more infohttp://www.google.com/patents/US20060019332?dq=No.+6,411,949

Zeitschrift für Physikalische ChemieZeitschrift für Physikalische Chemie

Surface Dilational Properties of Sodium 4-(1-methyl)-Alkyl Benzene Sulfonates: Effect of Alkyl Chain Length. Zhang, Ji-Chao / ...
more infohttps://www.degruyter.com/view/j/zpch.2013.227.issue-4/issue-files/zpch.2013.227.issue-4.xml

High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. | CureHunterHigh dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma. | CureHunter

Benzenesulfonates (administration & dosage, therapeutic use) *Carcinoma, Renal Cell (blood supply, drug therapy, pathology) ...
more infohttp://www.curehunter.com/public/pubmed22188900.do

Patent US3350319 - Aqueous detergent-inorganic builder concentrates - Google PatentsPatent US3350319 - Aqueous detergent-inorganic builder concentrates - Google Patents

Also useful are the sodium keryl benzene sulfonates. The amidoalkane sulfonates are characterized by the structure of an amide ... One group of these compounds, the sodium polypropylene benzene sulfonates, is described in United States Patent No. 2,477,383 ...
more infohttp://www.google.com/patents/US3350319?dq=U.S.+Patent+%23+5,723,324

Ingredients -- Detergents and SurfactantsIngredients -- Detergents and Surfactants

These were called branched-chain alkyl benzene sulfonates . Like soap, they could take hard minerals out of water, leaving it ... They were replaced by straight-chain alkyl benzene sulfonates, such as Sodium dodecylbenzinesulfonate and sodium ... Linear Alkyl benzene sulfonates (LAS). Straight-chain, anionic surfactants. Somewhat slow to biodegrade. Most common ... Alkyl benzene sulfonates (ABS). Branched-chain, anionic surfactants. Slow to biodegrade. Seldom used. ...
more infohttp://sci-toys.com/ingredients/detergents.html

US6345633B1 - Automatic dishwashing compositions containing water soluble cationic surfactants 
        - Google PatentsUS6345633B1 - Automatic dishwashing compositions containing water soluble cationic surfactants - Google Patents

Alkyl Benzene Sulfonates. R10ArSO3M. where R10 is an alkyl group of 8 to 18 carbon atoms, Ar is a benzene ring (C6H4) and M is ...
more infohttps://patents.google.com/patent/US6345633B1/en

Patent WO2013070560A1 - Surface treatment compositions including shielding salts - Google PatentsPatent WO2013070560A1 - Surface treatment compositions including shielding salts - Google Patents

Such linear alkyl benzene sulfonates are known as "LAS". Such surfactants and their preparation are described for example in U. ... Specific, non-limiting examples of anionic surfactants useful herein include: a) Cn-Cis alkyl benzene sulfonates (LAS); b) C10- ...
more infohttp://www.google.co.uk/patents/WO2013070560A1?cl=en

US7300506B2 - Ink formulations, print systems, and methods thereof 
        - Google PatentsUS7300506B2 - Ink formulations, print systems, and methods thereof - Google Patents

... linear alkyl benzene sulfonates; higher alkyl benzene sulfonates; benzene; toulene; xylene; cumenesulfonate; lignosulfonates; ...
more infohttps://patents.google.com/patent/US7300506

Patente US7101921 - Polymer composition - Google PatentesPatente US7101921 - Polymer composition - Google Patentes

Mixtures of alkyl benzenesulfonates and ethoxylated alkylphenols may be employed.. The first polymer or the second polymer may ...
more infohttp://www.google.es/patents/US7101921?dq=flatulence

Laundry detergent - Life Miracle Health Products | Wholesale Distributor | Liquid Vitamin | Liquid Collagen Protein | Nano...Laundry detergent - Life Miracle Health Products | Wholesale Distributor | Liquid Vitamin | Liquid Collagen Protein | Nano...

Linear Alkyl Benzene Sulfonates (LAS): These synthetic petrochemicals are normally listed as anionic surfactants on labels, ...
more infohttps://www.lifenatural.com/laundry-detergent/

recurrent hepatoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search enginerecurrent hepatoma drug therapy 2000:2010[pubdate] *count=100 - BioMedLib™ search engine

Benzenesulfonates / administration & dosage. Benzenesulfonates / adverse effects. Carcinoma, Hepatocellular / drug therapy. ... Benzenesulfonates / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Liver ... Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase ... Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Immunosuppressive Agents; 0 / Phenylurea ...
more infohttp://www.bmlsearch.com/?kwr=recurrent+hepatoma+drug+therapy+2000:2010%5Bpubdate%5D&cxts=100&stmp=b1

adenoma of the rat colon 2005:2010[pubdate] *count=100 - BioMedLib™ search engineadenoma of the rat colon 2005:2010[pubdate] *count=100 - BioMedLib™ search engine

Chemical-registry-number] 0 / 4-(4-cyclohexyl-2-methyloxazol-5-yl)-2-fluorobenzenesulfonamide; 0 / Benzenesulfonates; 0 / ...
more infohttp://www.bmlsearch.com/?kwr=adenoma+of+the+rat+colon+2005:2010%5Bpubdate%5D&cxts=100&stmp=b0

Iodine-glycerol as an alternative to lactophenol cotton blue for identification of fungal elements in clinical laboratory<...Iodine-glycerol as an alternative to lactophenol cotton blue for identification of fungal elements in clinical laboratory<...

TY - JOUR. T1 - Iodine-glycerol as an alternative to lactophenol cotton blue for identification of fungal elements in clinical laboratory. AU - Vignesh, R.. AU - Swathirajan, C. R.. AU - Solomon, S.. AU - Shankar, E. M.. AU - Murugavel, K. G.. AU - Paul, I.. AU - Waldrop, G.. AU - Solomon, Sunil. AU - Balakrishnan, P.. PY - 2013/1. Y1 - 2013/1. UR - http://www.scopus.com/inward/record.url?scp=84881059970&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=84881059970&partnerID=8YFLogxK. U2 - 10.4103/0255-0857.108752. DO - 10.4103/0255-0857.108752. M3 - Article. C2 - 23508444. AN - SCOPUS:84881059970. VL - 31. SP - 93. EP - 94. JO - Indian Journal of Medical Microbiology. JF - Indian Journal of Medical Microbiology. SN - 0255-0857. IS - 1. ER - ...
more infohttps://jhu.pure.elsevier.com/en/publications/iodine-glycerol-as-an-alternative-to-lactophenol-cotton-blue-for--3

W. Birchmeier Lab | Max Delbrück Center for Molecular MedicineW. Birchmeier Lab | Max Delbrück Center for Molecular Medicine

Seventy pyridazolon-4-ylidenehydrazinyl benzenesulfonates were prepared and evaluated in enzyme assays. The binding modes of ...
more infohttps://www.mdc-berlin.de/birchmeier

US Patent # 5,665,689. Cleaning compositions comprising mixtures of partially esterified full
     esterified and non-esterfied...US Patent # 5,665,689. Cleaning compositions comprising mixtures of partially esterified full esterified and non-esterfied...

C.sub.16 alkyl benzene sulfonates; C.sub.10 -C.sub.20 paraffin sulfonates; alpha olefin sulfonates containing about 10-24 ...
more infohttp://patents.com/us-5665689.html

Female Patient, Aged 56 Years (Patient 2).Coronal (a) a | Open-iFemale Patient, Aged 56 Years (Patient 2).Coronal (a) a | Open-i

Benzenesulfonates/adverse effects/therapeutic use*. *Carcinoma, Hepatocellular/complications/drug therapy*/mortality/pathology ... Benzenesulfonates/adverse effects/therapeutic use*. *Carcinoma, Hepatocellular/complications/drug therapy*/mortality/pathology ...
more infohttps://openi.nlm.nih.gov/detailedresult.php?img=PMC3038868_pone.0016978.g001&req=4

Patente US4698181 - Detergent compositions containing triethylenetetraminehexaacetic acid - Google PatentesPatente US4698181 - Detergent compositions containing triethylenetetraminehexaacetic acid - Google Patentes

Particularly preferred surfactants for use herein include alkyl benzene sulfonates, alkyl sulfates, alkyl polyethoxy sulfates ...
more infohttp://www.google.es/patents/US4698181

No FAQ available that match "benzenesulfonates"